GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hua Medicine (OTCPK:HUMDF) » Definitions » Policy Acquisition Expense

HUMDF (Hua Medicine) Policy Acquisition Expense


View and export this data going back to 2018. Start your Free Trial

What is Hua Medicine Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


Hua Medicine Business Description

Traded in Other Exchanges
Address
Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from PRC.